Skip to Content


Medically reviewed by Last updated on Sep 14, 2020.


(ra ni BIZ oo mab)

Index Terms

  • rhuFabV2

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravitreal [preservative free]:

Lucentis: 0.3 mg/0.05 mL (0.05 mL); 0.5 mg/0.05 mL (0.05 mL)

Solution Prefilled Syringe, Intravitreal [preservative free]:

Lucentis: 0.3 mg/0.05 mL (0.05 mL); 0.5 mg/0.05 mL (0.05 mL)

Brand Names: U.S.

  • Lucentis

Pharmacologic Category

  • Angiogenesis Inhibitor
  • Monoclonal Antibody
  • Ophthalmic Agent
  • Vascular Endothelial Growth Factor (VEGF) Inhibitor


Ranibizumab is a recombinant humanized monoclonal antibody fragment which binds to and inhibits human vascular endothelial growth factor A (VEGF-A). Ranibizumab inhibits VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.


Low levels are detected in the serum following intravitreal injection.

Half-Life Elimination

Vitreous: ~9 days

Use: Labeled Indications

Diabetic macular edema: Treatment of diabetic macular edema (DME).

Diabetic retinopathy: Treatment of diabetic retinopathy

Macular degeneration: Treatment of neovascular (wet) age-related macular degeneration (AMD)

Macular edema: Treatment of macular edema following retinal vein occlusion (RVO)

Myopic choroidal neovascularization: Treatment of myopic choroidal neovascularization (mCNV).


Hypersensitivity to ranibizumab or any component of the formulation; ocular or periocular infection

Canadian labeling: Additional contraindications (not in the US labeling): Active intraocular inflammation

Dosing: Adult

Age-related macular degeneration (AMD), neovascular (wet): Intravitreal: 0.5 mg once a month (approximately every 28 days). Frequency may be reduced (eg, 4 to 5 injections over 9 months) after the first 3 injections or may be reduced after the first 4 injections to once every 3 months if monthly injections are not feasible.

Note: A regimen averaging 4 to 5 doses over 9 months is expected to maintain visual acuity and an every-3-month dosing regimen has reportedly resulted in a ~5 letter (1 line) loss of visual acuity over 9 months, as compared to monthly dosing which may result in an additional ~1 to 2 letter gain.

Diabetic macular edema (DME): Intravitreal: 0.3 mg once a month (approximately every 28 days); in clinical trials, monthly doses of 0.5 mg were also studied (Massin 2010; Mitchell 2011)

Diabetic retinopathy (DR): Intravitreal: 0.3 mg once a month (approximately every 28 days)

Macular edema following retinal vein occlusion (RVO): Intravitreal: 0.5 mg once a month (approximately every 28 days)

Myopic choroidal neovascularization (mCNV): Intravitreal: 0.5 mg once a month (approximately every 28 days) for up to 3 months; may retreat if necessary.

Dosing: Geriatric

Refer to adult dosing.


Prefilled syringe: Syringe tray should be opened under sterile conditions. Snap off syringe cap (do not twist or turn) and attach 30 gauge ½ inch needle. Refer to manufacturer labeling for additional detailed information.

Vials: Remove contents from vial using a sterile 5 micron (19-gauge × 11/2-inch) filter needle attached to a 1 mL sterile Luer lock syringe (with marking to measure 0.05 mL). Discard filter needle and replace with a sterile 30 gauge × 1/2 inch needle for injection (do not use filter needle for intravitreal injection). Refer to manufacturer labeling for additional detailed information.


For ophthalmic intravitreal injection only. Each vial or prefilled syringe should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial or prefilled syringe should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before ranibizumab is administered to the other eye. Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure. Refer to manufacturer labeling for additional detailed information.


Store in original carton under refrigeration at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. Keep prefilled syringe in sealed tray until ready to use.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

As reported with AMD, RVO, and DME studies:


Cardiovascular: Arterial thromboembolism (AMD trials during first year: 2%; DME trials at 3 years: 11%)

Central nervous system: Foreign body sensation of eye (7% to 16%), headache (6% to 12%)

Hematologic & oncologic: Anemia (4% to 11%)

Neuromuscular & skeletal: Arthralgia (2% to 11%)

Ophthalmic: Conjunctival hemorrhage (47% to 74%), eye pain (17% to 35%), vitreous opacity (7% to 27%), increased intraocular pressure (7% to 24%), blurred vision (5% to 18%), intraocular inflammation (1% to 18%)

Note: Cataract, blepharitis, dry eye syndrome, eye irritation, increased lacrimation, maculopathy, ocular hyperemia, eye pruritus, and vitreous detachment occurred in >10% of patients, but also occurred either in similar percentages to the control or more often in the control in some studies.

Respiratory: Nasopharyngitis (5% to 16%), bronchitis (6% to 11%)

1% to 10%:

Cardiovascular: Peripheral edema (6%), atrial fibrillation (1% to 5%), cerebrovascular accident (AMD trials during 2 years: 3%; DME trials at 3 years: 2%)

Central nervous system: Peripheral neuropathy (1% to 5%)

Endocrine & metabolic: Hypercholesterolemia (3% to 7%)

Gastrointestinal: Nausea (9% to 10%), constipation (8%), gastroesophageal reflux disease (1% to 6%)

Genitourinary: Chronic renal failure (6%)

Immunologic: Antibody formation (1% to 9%), seasonal allergy (8%)

Infection: Influenza (3% to 7%)

Local: Bleeding at injection site (1% to 5%)

Ophthalmic: Retinal degeneration (1% to 8%)

Note: Conjunctival hyperemia, eye discomfort, posterior capsule opacification, and retinopathy occurred in 1% to 10% of patients, but also occurred in similar percentages to the control or more often in the control in some of the studies.

Renal: Renal failure (7%)

Respiratory: Upper respiratory tract infection (9%), cough (5% to 9%), sinusitis (3% to 8%), chronic obstructive pulmonary disease (3% to 6%)

Miscellaneous: Wound healing impairment (1%)

All indications: <1%, postmarketing, and/or case reports: Anterior chamber inflammation, anxiety, back pain, corneal edema, corneal erosion, coronary artery occlusion, decreased visual acuity, dizziness, endophthalmitis, epithelial keratopathy, eye discharge (lid margin), eyelid pain, hypoglycemia, iatrogenic traumatic cataracts, intestinal obstruction, photophobia, retinal pigment epithelium tear, rhegmatogenous retinal detachment, rhinorrhea, urticaria

As reported with choroidal neovascularization secondary to pathologic myopia (not in US labeling):


Ophthalmic: Conjunctival hemorrhage (11%)

Respiratory: Nasopharyngitis (11%)

1% to 10%:

Cardiovascular: Hypertension (3%)

Central nervous system: Headache (8%), migraine (2%)

Endocrine & metabolic: Diabetes mellitus (2%)

Gastrointestinal: Abdominal pain (3%), nausea (2%), toothache (2%), vomiting (2%)

Genitourinary: Urinary tract infection (3%), bacteriuria (2%)

Infection: Influenza (2%)

Local: Bleeding at injection site (4%)

Neuromuscular & skeletal: Back pain (2%), herniated disk (2%), limb pain (2%), osteoporosis (2%)

Ophthalmic: Punctate keratitis (8%), vitreous opacity (5%), dry eye syndrome (4%), eye pain (4%), increased intraocular pressure (3%), blepharitis (2%), conjunctivitis (2%), eyelid edema (2%), retinal hole without detachment (2%)

Respiratory: Upper respiratory tract infection (3%), pharyngitis (2%)

<1%: Allergic conjunctivitis, arthralgia, bronchitis, cataract, conjunctival edema, corneal erosion, cough, eye irritation, hepatic insufficiency, hypercholesterolemia, hypersensitivity, increased intracranial pressure, iridocyclitis, ocular hyperemia, pain at injection site, retinal hemorrhage, sciatica, tendonitis, uveitis, viral conjunctivitis (adenovirus), vitreous detachment


Concerns related to adverse effects:

• Endophthalmitis/retinal detachment: Intravitreous injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques should be used. Patients should be monitored for potential infection and report any signs of infection (eg, eye pain or redness, photophobia, blurred vision) immediately.

• Hypersensitivity reactions: Hypersensitivity may present as severe intraocular inflammation; instruct patients to report intraocular inflammation that increases with severity. Rare hypersensitivity reactions (including anaphylaxis) have been associated with another VEGF inhibitor, pegaptanib, occurring within several hours of use; monitor closely. Equipment and appropriate personnel should be available for monitoring and treatment of anaphylaxis.

• Increased intraocular pressure: Prior to and following intravitreal injection, intraocular pressure may increase. Onset is seen within 60 minutes postinjection. Monitor intraocular pressure before and after injection and manage accordingly.

• Thromboembolic events: Risk of thromboembolic events, particularly stroke, may be increased following intravitreal administration of VEGF inhibitors. Use caution in patients with known risk factors (eg, history of stroke, TIA).

Disease-related concerns:

• Diabetic macular edema (DME) and diabetic retinopathy (DR): Pooled analysis of trials involving DME and DR patients revealed a higher incidence of fatal events in patients treated with ranibizumab compared to control (3% in patients treated with 0.3 mg in the first 2 years compared to 1% in the control). Overall, the incidence of fatalities was consistent with deaths normally observed in patients with advanced diabetic complications; however, a potential association between fatal events and intravitreal administration of VEGF inhibitors cannot be excluded.

Monitoring Parameters

Intraocular pressure (prior to and 30 minutes following injection via tonometry); consider checking for perfusion of the optic nerve head immediately following injection; signs of infection/inflammation (for first week following injection); retinal perfusion, endophthalmitis; visual acuity.

Reproductive Considerations

Evaluate pregnancy status prior to use in females of reproductive potential. Women of reproductive potential should use effective contraception prior to initial dose, during treatment, and for at least 3 months after the last intravitreal injection (Peracha 2016).

Pregnancy Considerations

Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor; VEGF is required to achieve and maintain normal pregnancies. Reports of intravitreal VEGF inhibitor use in pregnancy (Peracha 2016), and information specific to use of ranibizumab in pregnancy, are limited (Fossum 2018; Jouve 2015; Sarhianaki 2012). Based on studies in nonpregnant adults, VEGF inhibitors can alter systemic concentrations of VEGF and placental growth factor following intravitreal administration (Peracha 2016; Zehtner 2015). Until additional information is available, use during the first trimester should be avoided and use later in pregnancy should be based on patient specific risks versus benefits (Peracha 2016; Polizzi 2015).

Patient Education

What is this drug used for?

• It is used to treat macular degeneration.

• It is used to treat macular swelling.

• It is used to treat some eye problems caused by diabetes.

• It may be given to you for other reasons. Talk with the doctor.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Dry eyes

• Floater in the eye

• Foreign body sensation in eye

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Weakness on 1 side of the body, trouble speaking or thinking, change in balance, drooping on one side of the face, or blurred eyesight

• Heart attack like chest pain; pain in arms, back, neck, jaw, or abdomen; shortness of breath; cold sweats; severe dizziness; passing out; or severe nausea or vomiting

• Vision changes

• Eye pain

• Severe eye irritation

• Eyelid swelling

• Eye discharge

• Bleeding in eye

• Eye redness

• Sensitivity to light

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.